FDA safety reporting consolidation
FDA will be consolidating all safety signal reporting systems as part of the formation of its bioinformatics board, Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb says June 21 at the Bank of America Washington Healthcare Conference. Currently, safety reports are received via five or six different systems and, consequently, "they get evaluated very differently and there is no intelligent screen built in through software to try to do an initial evaluation of some of the signals we get," he explains. FDA is currently working on an upgrade to its adverse event reporting system (1"The Pink Sheet" Feb. 13, 2006, p. 4)...
You may also be interested in...
Court finds US FDA did not impede Catalyst orphan exclusivity for Firdapse as it approved different indication for competing product. Biogen loses 10-year patent battle against competing multiple sclerosis drug makers.
Cover Three Nutritional Brain Defense marketer agrees to pull claims suggesting the supplement beverage can protect against traumatic brain injury after a test the firm on DHA submitted as support contained considerably higher levels of the ingredient than included in the product.
The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.